Risk of Infertility in Reproductive-Age Patients With Thyroid Cancer Receiving or Not Receiving 131I Treatment: A Nationwide Population-Based Cohort Study
- PMID: 39894986
- DOI: 10.1097/RLU.0000000000005570
Risk of Infertility in Reproductive-Age Patients With Thyroid Cancer Receiving or Not Receiving 131I Treatment: A Nationwide Population-Based Cohort Study
Abstract
Background: Fertility is the crucial concern for many survivors of cancer diagnosed as children, adolescents, and young adults. The objective of this study was to determine the risk of infertility in reproductive-age patients with thyroid cancer receiving or not receiving radioiodine treatment in Taiwan.
Methods: This nationwide population-based cohort study was conducted using data obtained from the Taiwan National Health Insurance Database from 2009 to 2019. A total of 20,259 thyroid cancer patients aged from 15 to 50 years (8037 did not receive 131I treatment, and 12,222 received 131I treatment) and 20,259 controls were enrolled. A Cox proportional hazards model was applied to estimate the risk of infertility in thyroid cancer patients receiving or not receiving 131I treatment in terms of hazard ratios and 95% confidence intervals.
Results: The incidence rates of infertility in thyroid cancer receiving 131I therapy, those not receiving 131I therapy, and controls were 5.55, 5.07, and 3.61 per 1000 person-years, respectively. Compared with thyroid cancer patients treated with a cumulative 131I dose of 4.44 GBq or less, the risk of infertility was not significantly increased in those treated with a cumulative 131I dose of more than 4.44 GBq (adjusted hazard ratio, 1.13; 95% confidence interval, 0.95-1.36).
Conclusions: The greatest increased risk of infertility in reproductive-age patients with thyroid cancer is associated with the fact that the patient has thyroid cancer regardless of 131I administration. 131I treatment or cumulative dose of 131I greater than 4.44 GBq did not further increase the risk of infertility.
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Conflicts of interest and sources of funding: none declared. This study was supported in part by China Medical University Hospital (DMR-113-048, DMR-113-060, DMR-113-061).
Similar articles
-
Risk of Breast Cancer in Patients with Thyroid Cancer Receiving or Not Receiving 131I Treatment: A Nationwide Population-Based Cohort Study.J Nucl Med. 2016 May;57(5):685-90. doi: 10.2967/jnumed.115.164830. Epub 2015 Dec 30. J Nucl Med. 2016. PMID: 26719377
-
Association Between 131I Treatment for Thyroid Cancer and Risk of Receiving Cataract Surgery: A Cohort Study from Taiwan.J Nucl Med. 2016 Jun;57(6):836-41. doi: 10.2967/jnumed.115.167197. Epub 2016 Feb 2. J Nucl Med. 2016. PMID: 26837336
-
131I treatment for thyroid cancer and risk of developing primary hyperparathyroidism: a cohort study.Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):253-9. doi: 10.1007/s00259-013-2541-5. Epub 2013 Aug 28. Eur J Nucl Med Mol Imaging. 2014. PMID: 23982456
-
[131 iodine: medical use. Carcinogenic and genetic effects].Ann Endocrinol (Paris). 1996;57(3):166-76. Ann Endocrinol (Paris). 1996. PMID: 8949411 Review. French.
-
Chronic myeloid leukaemia following 131I treatment for thyroid carcinoma: a report of two cases and review of the literature.Clin Endocrinol (Oxf). 1995 Nov;43(5):651-4. doi: 10.1111/j.1365-2265.1995.tb02932.x. Clin Endocrinol (Oxf). 1995. PMID: 8548952 Review.
References
-
- Lim H, Devesa SS, Sosa JA, et al. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA. 2017;317:1338–1348.
-
- Taiwan Cancer Registry. Cancer statistics. Incidence and mortality rates for top 10 cancers in Taiwan. Available at: https://twcr.tw/?page_id=1855&lang=en. Accessed August 22, 2024.
-
- Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.
-
- Boucai L, Zafereo M, Cabanillas ME. Thyroid cancer: a review. JAMA. 2024;331:425–435.
-
- Raffaelli M, Voloudakis N, Barczynski M, et al. European Society of Endocrine Surgeons (ESES) consensus statement on advanced thyroid cancer: definitions and management. Br J Surg. 2024;111:znae199.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical